AMGEN INC 8K

Amgen announced strong second quarter 2026 financial results with higher revenues, earnings, and free cash flow, updated 2026 guidance, and extensive pipeline and regulatory updates including obesity candidate MariTide, TAVNEOS regulatory engagement, and global expansion of oncology assets such as IMDELLTRA.

Amgen Inc. reported its second quarter 2026 results, highlighting a 10% year-over-year increase in total revenues to $10.1 billion and 9% growth in product sales driven largely by volume, with 22 products achieving double-digit sales growth and 17 annualizing above $1 billion; GAAP EPS rose 65% to $4.37 and non-GAAP EPS increased 4% to $6.29 as GAAP operating margin expanded to 36.8% and non-GAAP operating margin was 48.4%. The company generated $3.5 billion of free cash flow, raised its dividend 6% year over year to $2.52 per share, ended June 30, 2026 with $14.0 billion in cash and $57.3 billion of debt, and reaffirmed or updated 2026 guidance with total revenues expected between $38.2–$39.4 billion, GAAP EPS of $15.80–$17.08, non-GAAP EPS of $22.30–$23.50, and capital expenditures of about $2.6 billion. Operationally, Amgen reported strong growth from key drugs such as Repatha, EVENITY, TEZSPIRE, and IMDELLTRA, offset by material declines in Prolia, XGEVA, Otezla and certain oncology products due to biosimilar competition and pricing pressures including U.S. Medicare Part D price setting under the Inflation Reduction Act. The company provided extensive pipeline updates, including broad Phase 3 programs for obesity candidate MariTide, multiple ongoing late-stage cardiovascular and rare disease trials, discontinuation of further development of AMG 513 beyond an existing Phase 1 study, regulatory and clinical developments for TAVNEOS amid an FDA request for voluntary market withdrawal, partial clinical holds on subcutaneous blinatumomab studies, and continued global expansion and combination studies for IMDELLTRA in small cell lung cancer and xaluritamig in prostate cancer. Management emphasized confidence in long-term growth driven by its six key growth drivers, expanded indications, and a deep late-stage pipeline in obesity, cardiovascular disease, oncology, inflammation, rare diseases, and biosimilars.

Filing Facts

CIK

318154

Ticker

AMGN

Form

8K

Source Type

fda

Accession

0000318154-26-000124

Alert Tier

9